IP Library Granted Patent US 10,648,974
Granted Patent B2
US 10,648,974 · App. 15/314,420 · Granted May 12, 2020

Ethyl glucuronide lateral flow test strips, immunoassays, devices and methods for detecting or measuring thereof

Inventors: Paul Kenneth Johnson (Blue Earth, MN); Jacqueline Ann Gale (Basingstoke, GB)
Assignee: CAREHEALTH AMERICA CORPORATION
G01N33/558A61B5/6861A61B10/00A61B10/007A61B16/00G01N33/581G01N33/585G01N33/64G01N33/98A61B10/0045A61B2010/0006A61B2010/0009G01N2400/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,648,974
App. No.
15/314,420
Granted
May 12, 2020
Kind
B2
Abstract

Ethyl glucuronide (EtG) lateral flow immunoassay test strips, devices, and methods, useful for testing for alcohol ingestion for alcohol abuse or related diseases and treatment monitoring.

Claims (42)

1. An Ethyl glucuronide (EtG) lateral flow test strip immunoassay system for detecting ethyl glucuronide in a fluid sample, the system comprising:

(a) a lateral flow test strip, the test strip comprising:

(i) at least one type of capillary flow material capable of reproducibly providing lateral flow of the fluid sample through the test strip to reproducibly interact and detect EtG using a detectably labeled EtG-specific antibody; and a first detectable label and a second detectable label comprised in the test strip, the test strip providing:

(1) a positive result, with a first colored band only developing;

(2) a negative result, with both a second colored band and the first colored band developing; or

(3) an invalid result, with only the second colored band developing or no bands;

(ii) a sample application area, comprising a sample application component;

(iii) a labeled EtG labeled antibody area, comprising a detectably labeled EtG specific antibody provided in or to the test strip material, the detectably labeled EtG specific antibody comprising an EtG specific antibody conjugated to a detectable label component and soluble in or conducted along the test strip by capillary action of the fluid sample after application to the test strip;

(iv) a first detection area comprising the first detectable label as a first labeled moiety that binds the detectably labeled EtG specific antibody, when the concentration of EtG in the fluid sample is below a pre-selected threshold value between 100 and 2000 ng/mL;

wherein the binding of the detectably labeled EtG specific antibody below the pre-selected threshold results in the negative result with both the first colored band and the second colored band; and

wherein the detectably labeled EtG specific antibody does not detectably or significantly bind the first detectable label and also does not provide the negative result, when the EtG in the fluid sample is above the pre-selected threshold value;

(v) a second detection area comprising the second detectable label as a second labeled moiety that binds the detectably labeled EtG specific antibody, when the concentration of the EtG in the fluid sample is above the pre-selected threshold value between 100 and 2000 ng/mL; and

wherein the binding of the detectably labeled EtG specific antibody above the pre-selected threshold results in the positive result with only the first colored band; and

wherein the detectably labeled EtG specific antibody does not detectably or significantly bind the first detectable label, when the EtG in the fluid sample is above the pre-selected threshold value; and

wherein, when the assay is invalid, the binding of the detectably labeled EtG specific antibody results in the invalid result with only the second colored band, or no bands; and wherein the detectably labeled EtG specific antibody does not detectably or significantly bind the second detectable label.

2. The immunoassay system as in claim 1 , wherein the threshold value is 500, 750, or 1000 ng/mL.

3. The immunoassay system as in claim 1 , wherein the detectable label is colloidal or latex gold.

4. The immunoassay system as in claim 1 , wherein the EtG specific antibody is monoclonal.

5. The immunoassay system as in claim 4 , wherein the affinity of the EtG specific antibody for EtG is at least 10 −7 K D .

6. Original) The immunoassay system as in claim 1 , wherein the detectable label is comprised of an enzyme, enzyme fragment or enzyme donor fragment.

7. The immunoassay system as in claim 1 , wherein the detectable label is comprised of an enzyme, enzyme fragment or enzyme donor fragment.

8. A method for an ethyl glucuronide (EtG) lateral flow test strip immunoassay for detecting ethyl glucuronide in a fluid sample above or below a threshold value, the method comprising:

(a) providing a lateral flow test strip, the test strip comprising:

(i) at least one type of capillary flow material capable of reproducibly providing lateral flow of a urine, bodily fluid or tissue sample through the test strip to reproducibly interact and detect EtG using a detectably labeled EtG-specific antibody; and a first detectable label and a second detectable label comprised in the test strip, the test strip providing:

(1) a positive result, with a first colored band only developing;

(2) a negative result, with both a second colored band and the first colored band developing; or

(3) an invalid result, with only the second colored band developing or no bands;

(ii) a sample application area, comprising a sample application component;

(iii) a labeled EtG labeled antibody area , comprising a detectably labeled EtG specific antibody provided in or to the test strip material, the detectably labeled EtG specific antibody comprising an EtG specific antibody conjugated to a detectable label component and soluble in or conducted along the test strip by capillary action of the urine or control sample after application to the test strip;

(iv) a first detection area comprising the first detectable label as a first labeled moiety that binds the detectably labeled EtG specific antibody, when the concentration of EtG in the urine or control sample is below a pre-selected threshold value between 100 and 2000 ng/mL;

wherein the binding of the detectably labeled EtG specific antibody below the pre-selected threshold results in the negative result with both the first colored band and the second colored band; and

wherein the detectably labeled EtG specific antibody does not detectably or significantly bind the first detectable label and also does not provide the negative result, when the EtG in the urine or control sample is above the pre-selected threshold value;

(v) a second detection area comprising the second detectable label as a second labeled moiety that binds the detectably labeled EtG specific antibody, when the concentration of the EtG in the urine or control sample is above the pre-selected threshold value between 100 and 2000 ng/mL; and

wherein the binding of the detectably labeled EtG specific antibody above the pre-selected threshold results in the positive result with only the first colored band; and

wherein the detectably labeled EtG specific antibody does not detectably or significantly bind the first detectable label, when the EtG in the urine or control sample is above the pre-selected threshold value; and

wherein, when assay is invalid, the binding of the detectably labeled EtG specific antibody results in the invalid result with only the second colored band, or no bands; and wherein the detectably labeled EtG specific antibody does not detectably or significantly bind the second detectable label;

(b) applying the fluid sample to the test strip; and

(c) determining whether the fluid sample comprises EtG above or below the threshold.

9. The method according to claim 8 , wherein the threshold value is 500, 750, or 1000 ng/mL.

10. The method according to claim 8 , wherein the detectable label is colloidal or latex gold.

11. The method according to claim 8 , wherein the EtG specific antibody is monoclonal.

12. The method according to claim 8 , wherein the affinity of the EtG specific antibody for EtG is at least 10 −7 K D .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2019
From: JOHNSON, PAUL KENNETH
To: CAREHEALTH AMERICA CORPORATION
Reel/Frame 048228/0012 →
SURRENDER OF SECURED PROPERTY Recorded Feb 4, 2019
From: EXPRESS DIAGNOSTICS INT'L, INC.
To: FARMERS & MERCHANTS SAVINGS BANK
Reel/Frame 048232/0592 →
AGREEMENT AND BILL OF SALE Recorded Feb 4, 2019
From: FARMERS AND MERCHANTS SAVINGS BANK
To: CAREHEALTH AMERICA CORPORATION
Reel/Frame 048232/0782 →
SECURITY INTEREST Recorded Sep 18, 2018
From: EXPRESS DIAGNOSTICS INT'L, INC.
To: CHRISTENSEN FONDER DARDI HERBERT PLLC
Reel/Frame 047103/0135 →
Continuity (1)
Related Publication 20170191996A1 · Jul 6, 2017